Lyme disease is the fastest growing vector borne disease in the United States. Though easily curable in its early stage, Lyme disease can be difficult to diagnose. The current laboratory tests to help in diagnosing Lyme are accurate only about 50% of the time in the early onset of infection. This poor "sensitivity" leads to thousands of missed diagnoses, allowing the disease to advance to often devastating effect. Once established, Lyme disease mimics the symptoms of many other diseases, further complicating diagnosis. It is extremely difficult to treat at its more advanced stage, when it has spread through the body.
What's the problem with today's laboratory tests? The current tests depend on detecting evidence of your body's immune system fighting Lyme disease: antibodies.... [Read More]
A Crowd Note modifies the typical convertible note so that the crowd does not automatically convert to equity shareholders on the next financing and remain off the issuer’s capitalization table, but the crowd will still participate in any exit as if they had converted to equity. If there is no future financing, the holders of the Crowd Note still have upside, but could miss out significantly.
August 21, 2020
November 13, 2020
Open to Investors
Omar Green, PhD
Omar is CEO, also leading the development of our technology as it relates to materials and spectroscopy. Co-Founding with Joel Tabb, PhD, Omar was inspired to improve Lyme disease diagnostics when a softball teammate had his life upended in the prime of life by a missed diagnosis, which led to a debilitating battle with Lyme disease
Joel Tabb, PhD
Joel is a co-founder and also runs the development of our technology relating to biology. Joel and Co-Founder Omar Green, PhD, were work colleagues at Agave Biosystems. Their complementary scientific backgrounds led to the idea to combine aptamers and surface enhanced Raman scattering to create a new class of sensitive diagnostics
CHIEF BUSINESS OFFICER
Dean is an experienced life sciences executive, with a track record of successfully commercializing new diagnostic tests.
Conversion Discount: 20%
Interest Rate: 8%
There are no additional research reports currently.